Literature DB >> 24671822

High serum carbohydrate antigen 125 concentration can predict serous effusion but not gastrointestinal malignancy in male patients.

Xian Zhu1, Wei Zhou, Yan Chen, Jun Gao, Fanyang Kong, Jie Liu, Zhaoshen Li, Jun Gao, Yu Bai.   

Abstract

This study aims to evaluate the diagnostic accuracy of carbohydrate antigen 125 (CA125) in male patients for predicting gastrointestinal malignant diseases. One hundred twenty consecutive male patients underwent CA125 test after admission to the Department of Gastroenterology in Changhai Hospital, the Second Military Medical University, from April to June 2013. Data of age, main symptoms, and final diagnosis were summarized. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of CA125 for malignancy were estimated, and the receiver operating characteristic (ROC) analysis and the area under the curve (AUC) were also performed to evaluate the diagnostic value of CA125 in male patients. The PPV, NPV, PLR, and NLR of CA125 in malignancy were 55 %, 69 %, 1.90, and 0.71, respectively. However, we found that an elevated serum CA125 level was more common in male patients with serous effusion than those with malignancy. The PPV, NPV, PLR, and NLR of CA125 in serous effusion were 85 %, 96 %, 12.70, and 0.09, respectively. In the ROC analysis, the AUC values for CA125 was 0.96 (95 % confidence interval, 0.93-0.99) for discriminating patients with serous cavity effusion from those without serous effusion. CA125 has a higher accuracy in detecting serous effusion than malignancy in male patients with gastrointestinal diseases. It is of little significance for male patients to perform CA125 test for malignancy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671822     DOI: 10.1007/s13277-014-1625-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Re. Zuckerman et al.--Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites.

Authors:  R Sari; B Yildirim; A Sevinc; F Hilmioglu
Journal:  Am J Gastroenterol       Date:  2001-01       Impact factor: 10.864

2.  CA125 production by the peritoneum: in-vitro and in-vivo studies.

Authors:  M Epiney; C Bertossa; A Weil; A Campana; P Bischof
Journal:  Hum Reprod       Date:  2000-06       Impact factor: 6.918

3.  The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.

Authors:  Catharine M Sturgeon; Michael J Duffy; Graeme Walker
Journal:  Ann Clin Biochem       Date:  2011-07       Impact factor: 2.057

4.  Diagnostic accuracy of features predicting lower gastrointestinal malignancy: a colonoscopy database review of 10,603 Chinese patients.

Authors:  Y Bai; C Xu; D-W Zou; J Gao; Z-S Li
Journal:  Colorectal Dis       Date:  2010-03-10       Impact factor: 3.788

5.  Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.

Authors:  A Sevinc; S Buyukberber; R Sari; Y Kiroglu; H M Turk; M Ates
Journal:  Gynecol Oncol       Date:  2000-05       Impact factor: 5.482

6.  Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.

Authors:  Mirte M Streppel; Audrey Vincent; Radha Mukherjee; Nathaniel R Campbell; Shih-Hsun Chen; Konstantinos Konstantopoulos; Michael G Goggins; Isabelle Van Seuningen; Anirban Maitra; Elizabeth A Montgomery
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

Review 7.  Tumour biomarkers in heart failure: is there a role for CA-125?

Authors:  Mehmet Birhan Yilmaz; Maria Nikolaou; Alain Cohen Solal
Journal:  Eur J Heart Fail       Date:  2011-04-26       Impact factor: 15.534

8.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

9.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

10.  Ovarian cancer, version 3.2012.

Authors:  Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Robert A Burger; Mariana Castells; Lee-may Chen; Larry Copeland; Marta Ann Crispens; David Gershenson; Heidi Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Steven W Remmenga; Paul Sabbatini; Joseph T Santoso; Russell J Schilder; Julian Schink; Nelson Teng; Theresa L Werner; Miranda Hughes; Mary A Dwyer
Journal:  J Natl Compr Canc Netw       Date:  2012-11-01       Impact factor: 11.908

View more
  1 in total

1.  Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women.

Authors:  Chi-Jung Huang; Jeng-Kai Jiang; Shih-Ching Chang; Jen-Kou Lin; Shung-Haur Yang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.